With Congress stuck, the administration holds the key to whether Americans will see meaningful reductions in prescription drug costs. So far, though, they’ve punted.
Medicare
Posted inHealth and Social Policy
Medicare Advantage Is a Massive Scam
The program rips off both the taxpayer and its own enrollees.
Posted inHealth and Social Policy
Insulin Bill Won’t Help Many Insulin Patients
A proposed cap on co-payments won’t do anything for those without insurance.
Posted inMoney, Politics, and Power
The Corporate Past of Jeffrey Zients
The administration’s highest-ranking COVID official built his wealth through billing practices that have been alleged as fraud, triggering hundreds of millions in fines.
Posted inTAP
Invisible Privatization
Today on TAP: Medicare, the crown jewel of American health care, is being stealthily devoured by health insurance companies.
Posted inHealth and Social Policy
Biden’s Big Chance to Lower Drug Prices
A decision on whether to open a costly cancer drug to generic competition will be made shortly. It doesn’t require congressional approval.
Posted inHealth and Social Policy
The Dark History of Medicare Privatization
Medicare Advantage was supposed to be a money-saver. It’s now become a costly, unaccountable cash cow for private insurance companies that is swallowing traditional Medicare.
Posted inHealth and Social Policy
Biden Regulators Take Action on Hidden Pharma Monopolies
A proposed rule would eliminate the ability of pharmacy benefit managers to extract profits after a prescription drug is sold.
Posted inPolitics
Toxic Ads and How to Counter Them
Anticipating and rebutting likely lines of attack is the best strategy, on both partisan and civic grounds.
Posted inBuilding Back America
The Drug Price/Tax Break Quid Pro Quo
Democrats in high-tax states cut a deal on the Build Back Better Act.